NAD+ and Resveratrol: Why They're Paired and What Human Studies Show

NAD+ and resveratrol are paired because of a sirtuin theory: sirtuin enzymes run on NAD+, and early lab studies proposed resveratrol as a sirtuin activator. It's a tidy story, but no human trial has tested NAD+ and resveratrol together, so each ingredient has to earn its place on its own evidence.

Here's what that evidence says, and the safety points to check before you combine them.

Search "NAD resveratrol" and you'll find combo bottles with long ingredient lists and longer promises. For the bigger picture on NAD+ itself, see what NAD+ research shows.

Should you take NAD+ with resveratrol?

Take them together only if each one makes sense for you on its own. The pairing rests on a sirtuin theory built in test tubes, yeast and mice, which makes it a hypothesis rather than a tested combination.

Our search of Europe PMC on October 2, 2026 found no published human trial of NAD+ taken with resveratrol, and the closest study used two related molecules instead.

So choose NAD+ for NAD+, decide on resveratrol based on its own evidence and safety profile, and keep them in separate bottles so you know exactly how much of each you take. On prescription medicines? Add a quick pharmacist check, because resveratrol carries a known interaction flag.

Why are NAD+ and resveratrol sold together?

Because sirtuins sit at the center of both stories. Sirtuins are a family of enzymes that remove acetyl tags from proteins, and they need NAD+ to do that job. SIRT1, one of seven human sirtuins, has been linked to the pathways involved in calorie restriction, which is why it drew so much research attention. (Here's what NAD+ does in cells beyond sirtuins.)

Resveratrol entered the picture in 2003, when a study in Nature reported that it activated human SIRT1 in lab tests and, in yeast, mimicked calorie restriction and extended lifespan by 70%. Three years later, a 2006 mouse study found that resveratrol shifted the health of middle-aged mice on a high-calorie diet toward that of mice on a standard diet and significantly increased their survival.

Put those findings next to NAD+ and the marketing pitch writes itself: NAD+ is the fuel, resveratrol is the accelerator. Yeast and mice aren't people, though, and the accelerator half of that story has been argued about ever since.

Does resveratrol really activate sirtuins?

It depends on how you test it, and scientists still disagree.

In 2010, a Pfizer team (Pacholec and colleagues) tested resveratrol against natural SIRT1 substrates: a peptide with no added label, and full-length proteins. Resveratrol didn't activate SIRT1 with any of them. It only appeared to work when the test peptide carried a fluorescent tag, and the team showed the compounds bound to that tagged peptide directly.

They also found resveratrol acted on many other targets, including receptors, enzymes, transporters and ion channels, and concluded it is not a direct SIRT1 activator.

In 2013, a Harvard-led team (Hubbard and colleagues) answered back. They found that SIRT1 can be activated directly through an allosteric mechanism, meaning the activator binds at a site away from the enzyme's active center.

Hydrophobic motifs in natural SIRT1 targets such as PGC-1α and FOXO3a helped that activation along. A single amino acid in SIRT1, Glu230, was critical for activation by every previously reported type of sirtuin activator.

The disagreement comes down to substrates and test conditions, and all of it is test-tube and cell research, not studies in people. "Sirtuin activator" on a supplement label is a live scientific debate squeezed into a two-word claim wearing a lab coat.

What do human studies show for resveratrol?

Two things stand out: your body absorbs resveratrol well but converts most of it almost immediately, and trials of its metabolic effects point in different directions.

Start with absorption. In a 2004 study of six volunteers given a 25 mg oral dose of labeled resveratrol, at least 70% was absorbed, yet only trace amounts of unchanged resveratrol (under 5 ng/mL) showed up in the blood.

The intestine and liver rapidly attach sulfate and glucuronide groups to it, and the researchers described its systemic bioavailability as very low. Your gut and liver aren't spectators here; they're bouncers.

The metabolic trials disagree with each other. In a 30-day crossover trial, 11 healthy obese men took 150 mg a day of resveratrol (the branded ingredient resVida) or placebo. On resveratrol, sleeping and resting metabolic rate dropped, muscle SIRT1 and PGC-1α protein rose, and liver fat, blood glucose, triglycerides, the liver enzyme ALT, inflammation markers and systolic blood pressure all fell. The authors described the changes as mimicking calorie restriction.

A much bigger dose didn't repeat that. In a 4-week randomized trial, 24 obese but otherwise healthy men took 500 mg of trans-resveratrol three times a day (1.5 g a day) or placebo. Resveratrol had no effect on insulin sensitivity, the main outcome.

Blood pressure, resting energy expenditure, fat burning, fat stored in and around organs, and inflammatory and metabolic markers didn't change either. The authors wrote that the result raises doubt about resveratrol as a supplement for metabolic disorders.

A gentler dose in a different group also came up empty. In a 12-week randomized trial, 29 nonobese postmenopausal women with normal glucose tolerance took 75 mg a day of resveratrol (15 women) or placebo (14 women). Blood resveratrol rose, but body composition, resting metabolic rate, blood lipids, inflammation markers, insulin sensitivity and SIRT1 in muscle and fat didn't change.

The widest view comes from a 2026 umbrella review of 45 systematic reviews covering 129 associations between resveratrol and health measures. Of 35 statistically significant associations, four reached high-certainty evidence: waist circumference 0.80 cm smaller, total cholesterol 0.19 mmol/L lower in overweight adults, and systolic and diastolic blood pressure 7.97 and 3.55 mmHg lower in people with type 2 diabetes. These are changes in measured markers within specific groups.

Resveratrol in people: what key studies found

Study	Who	Daily dose and length	What happened
Walle 2004	6 volunteers	Single 25 mg dose	At least 70% absorbed; under 5 ng/mL of unchanged resveratrol in blood
Timmers 2011	11 healthy obese men	150 mg for 30 days	Lower metabolic rate, glucose, triglycerides and inflammation markers; higher muscle SIRT1 protein
Yoshino 2012	29 nonobese postmenopausal women	75 mg for 12 weeks	No change in metabolic measures or in muscle and fat SIRT1
Poulsen 2013	24 obese, otherwise healthy men	1.5 g for 4 weeks	No effect on insulin sensitivity, blood pressure, resting energy expenditure, fat burning, organ fat or inflammatory and metabolic markers
Sun 2026 (umbrella review)	45 systematic reviews of randomized trials	Varied	4 high-certainty findings: waist, total cholesterol, and blood pressure in type 2 diabetes

Has anyone tested NAD+ and resveratrol together?

Not in people. The nearest thing is a trial of two related molecules.

In a 2017 randomized, double-blind trial, 120 healthy adults aged 60 to 80 took placebo or NRPT daily for eight weeks. NRPT combines nicotinamide riboside (NR), an NAD+ precursor vitamin found in milk, with pterostilbene, a naturally occurring analog of resveratrol found in blueberries.

At the standard dose (250 mg of NR plus 50 mg of pterostilbene), whole-blood NAD+ was about 40% higher after four weeks than with placebo; at double the dose it was about 90% higher, and the rise held through week eight.

There were no serious adverse events, though total and LDL cholesterol rose slightly, more so at the double dose. Elysium Health, which sells NRPT, funded the trial, and most of its authors worked for the company.

For NAD+ on its own, the most direct human data come from a 2026 randomized, placebo-controlled trial. Sixty healthy adults aged 45 to 75 took a proprietary oral NAD+ powder (LNAD+) or placebo for five days, with 50 in the main analysis. NAD inside blood cells, measured in whole blood, rose 53% versus placebo by day 6, while NAD in plasma didn't change.

Neither trial answers the combination question: one swapped in different molecules, and the other tested a proprietary NAD+ powder alone. The pairing is untested, not disproven. For how these results fit the wider evidence, see our review of NAD+ benefits research, and for the precursor version of this question, our guide to NMN and resveratrol.

What are the downsides of resveratrol?

The two to know about are stomach upset at high doses and a possible interaction with some medicines.

The European Food Safety Authority (EFSA) assessed synthetic trans-resveratrol in 2016 and concluded that 150 mg a day for adults does not raise safety concerns. Its panel also noted:

• Stomach effects at high doses. Diarrhea or other gastrointestinal symptoms were reported in four uncontrolled studies at 1 g a day or more. In one of them, a 29-day study of 40 healthy volunteers, the 2.5 g and 5 g daily doses caused mild to moderate gastrointestinal symptoms.
• A possible medication interaction. A resveratrol metabolite, trans-resveratrol sulfate, could inhibit CYP enzymes in humans and may interact with medicines that are mainly broken down by the enzyme CYP2C9.
• Pregnancy. The safety conclusion covered adults at 150 mg a day, and the panel noted that pregnant rats may be especially susceptible, based on animal testing.

If you take any prescription medicine, ask a pharmacist to check resveratrol against your list before you start. If you're pregnant or breastfeeding, talk with your clinician first.

Quick answers

What does NAD+ with resveratrol do?

No human study has measured what the pair does together. On their own, a proprietary oral NAD+ powder raised NAD inside blood cells by 53% versus placebo in a five-day trial, and resveratrol's best-supported human effects are changes in waist size, cholesterol and blood pressure in specific groups. The idea that the two work better together remains a lab hypothesis.

What is the downside of taking NAD+?

Human data on oral NAD+ are short-term so far. In the five-day trial above, the NAD+ powder was very well tolerated: symptom rates were similar to placebo, and there was one mild case of nausea. Our guide to NAD+ side effects and safety covers what's known in more detail.

What supplements should not be taken with NAD+?

No interaction studies of oral NAD+ turned up in our research, so there's no verified "avoid" list. If you take prescription medicines or several supplements, a pharmacist can check the whole list, including resveratrol and its CYP2C9 flag. Our NAD+ safety guide covers the rest.

Where Infinite Labs NAD+ fits

If you want NAD+ itself rather than a crowded longevity blend, Infinite Labs NAD+ capsules are a strong pick. Each veggie capsule delivers 500 mg of NAD+ with 2.5 mg of BioPerine, a standardized black pepper extract, and every amount is printed on the label.

There's no resveratrol and no proprietary blend: a plant-based hypromellose capsule and Nu-FLOW, a rice-hull flow aid, complete the ingredient list.

Adults take one capsule daily with food, or as recommended by a qualified healthcare professional, and each bottle holds 30 servings. It's third-party tested and made in GMP-certified facilities, and certificates of analysis are available on request.

A single-ingredient capsule also keeps stacking simple: anything you add sits in its own bottle. Still comparing NAD+ products? Our guide to choosing an NAD+ supplement walks through form, dose and label checks.

The practical takeaway

• The pairing comes from a lab and animal sirtuin theory, and whether resveratrol directly activates SIRT1 is still debated.
• Resveratrol is well absorbed, but little reaches your blood unchanged, and its human trials conflict.
• No human trial has tested NAD+ with resveratrol, so judge each ingredient on its own evidence.
• Adding resveratrol? Mind its two safety flags: stomach upset at 1 g a day or more, and a possible interaction with medicines broken down by CYP2C9.

Want NAD+ on its own terms? Infinite Labs NAD+ keeps it to one clearly labeled 500 mg capsule a day.

Sources

• Howitz KT et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003.
• Baur JA et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006.
• Pacholec M et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. Journal of Biological Chemistry. 2010.
• Hubbard BP et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science. 2013.
• Walle T et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition. 2004.
• Timmers S et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism. 2011.
• Yoshino J et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metabolism. 2012.
• Poulsen MM et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013.
• Sun JN et al. Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. Nutrition Journal. 2026.
• Dellinger RW et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably. NPJ Aging and Mechanisms of Disease. 2017.
• Kornilov SA et al. Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. GeroScience. 2026.
• EFSA Panel on Dietetic Products, Nutrition and Allergies. Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal. 2016;14(1):4368.
• Brown VA et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Research. 2010.

Educational information, not medical advice. Infinite Labs NAD+ is not intended to diagnose, treat, cure, or prevent any disease.

About the author

Arjun Sareen is CEO of Infinite Labs and Infinite Labs Digital and a contributor to the Infinite Labs Journal. This brand-owned guide provides educational information, not individual medical advice.